SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
SELECTED ABSTRACTS FOR POSTER PRESENTATIONS
IN ALPHABETIC ORDER ACCORDING TO THE NAME OF THE FIRST AUTHOR
CLINICAL POSTERS
Poster 5: CASTLEMAN DISEASE – A REVIEW OF 8 CASES FROM A SINGLE CENTRE
Sherry Abraham
Poster 6: BACK TO BASICS – A CASE OF HEAVILY PRE-TREATED MULTIPLE MYELOMA
RELAPSE SUCCESSFULLY RETREATED WITH BORTEZOMIB
Cátia Almeida, Adriana Roque, Catarina Geraldes and Ana Isabel Espadana
Poster 7: A DOUBLE-HIT OF LIFE-THREATENING VIRAL INFECTIONS IN A PATIENT WITH
MULTIPLE MYELOMA TREATED WITH DARATUMUMAB-BASED REGIMEN
Athanasia Apsemidou, Sofia Chatzileontiadou, Anna Xanthopoulou, Christina Frouzaki,
Dimitrios Kotsos, Maria Papaioannou and Evdoxia Hatjiharissi
Poster 8: HYPERVISCOSITY AS FIRST PRESENTATION SYMPTOM OF PRIMARY IGM
LAMBDA PLASMA CELL LEUKEMIA WITH A LOW LEVEL MONOCLONAL
COMPONENT
Patrizia Bernuzzi, Simona Bassi and Antonio Lazzaro
Poster 9: ONE PATIENT, TWO HEMATOLOGICAL DISEASES
Eliana Cajigas, Maria Sarmento, Margarida Guimarães, Carlos Flores, Vitória Cabral
Poster 10: GAIN OF CHROMOSOME 1Q MAY BE ASSOCIATED WITH HIGH
REFRACTORINESS TO THERAPY IN MULTIPLE MYELOMA PATIENTS
Sofia Chatzileontiadou, Anna Xanthopoulou, Athanasia Apsemidou, Dimitrios Kotsos,
Christina Frouzaki, Maria Papaioannou and Evdoxia Hatjiharissi
Poster 11: PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN THE PHASE
1B/2 CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Adam D. Cohen, Parameswaran Hari, Myo Htut, Jesus G. Berdeja, Deepu Madduri, Saad
Z. Usmani, Alicia J. Allred, Yunsi Olyslager, Arnob Banerjee, Jenna D. Goldberg, Jordan
M. Schecter, Carolyn C. Jackson, Katharine S. Gries, John Fastenau, William Deraedt,
Marlene J. Carrasco-Alfonso, Muhammad Akram, Farah Hossain, Rebecca Crawford,
Ross Morrison, Lynda Doward, Andrzej Jakubowiak and Sundar Jagannath
Poster 12: PLASMABLASTIC PLASMA CELL MYELOMA – A CHALLENGING DIAGNOSIS
Rita Costa E Sousa, Adriana Roque, Marília Gomes, José Pedro Carda and Lenka
RuzicKova
Poster 13: A NEWLY DIAGNOSED PATIENT WITH UNUSUAL BLEEDING AND MULTIPLE
MYELOMA, FOUND TO HAVE A BICLONAL GAMMOPATHY
M N Dilhani, W D D Prasanni, T Dissanayake and Senani Williams